Predictors of treatment duration in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide: a post hoc analysis of ARCHES.

Andrew J. Armstrong, MD, MS

May 31, 2026; 9:00 AM CDT

Abstract & Presentation

Abstract & e-poster

The content displayed at the congress

video

Video

Link to video summary

Abstract Plain Language Summary (aPLS)

Abstract Plain Language Summary (aPLS)

Abstract content summarized in plain language.

Data supplement

Data supplement

Data supplement

Data supplement

video

Video

Link to video summary

These materials are for personal use only and not for reproduction.